CD19 and systemic lupus erythematosus: Preclinical data suggested compelling evidence that CD19-targeted CAR CD8+ T cells possess the capability to effectively deplete CD19+ B cells, leading to the elimination of autoantibody production and subsequent reversal of lupus manifestations in both NZB/W F1 and MRL/lpr mice models [21].